Pharmaceutical companies are named again for sales with gold

On April 16, the Heilongjiang Provincial Commission for Discipline Inspection issued an investigation notice involving medical anti-corruption.

The notification showed that Lin Zhiguo (non-CCP member), former vice president of the First Affiliated Hospital of Harbin Medical University, was suspected of serious violations of the law and voluntarily surrendered.

According to an article published by the Heilongjiang Provincial Commission for Discipline Inspection and Supervision on March 25, "Sealing the two ends, blocking the middle, weaving the anti-corruption prevention and control network in the field of medicine purchase and sale", a few days ago, a serious meeting on the clean purchase and sale of medical consumables was held in the office building of Harbin Medical University.

It can be seen that in recent years, relevant departments have been stepping up efforts to advance medical anti-corruption work, and hospitals are also paying more and more attention to compliance.

The problem of gold sales has attracted much attention

Recently, the Ministry of Finance and the National Medical Insurance Bureau announced the results of joint enforcement for the first time, officially reporting the results of accounting information quality inspections of pharmaceutical companies, and imposing administrative penalties on 19 pharmaceutical companies.

Subsequently, on April 15, the website of the State Supervision Commission of the Central Commission for Discipline Inspection released the article "In-Depth Concern | Sword Refers to Pharmaceutical Companies with Gold Sales", focusing on the analysis of the results of this inspection.

It is understood that the audit of pharmaceutical companies began two years ago.

According to the requirements, the content of this inspection includes the pharmaceutical companies’ compliance with accounting laws and regulations, financial accounting systems, internal control regulations, etc.

According to the above article, Liu Feng, the second-level inspector of the Bureau of Supervision and Evaluation of the Ministry of Finance, summarized from three aspects: “After inspection, he found out the cause of the falsely high drug prices, and deterred the illegal behavior of pharmaceutical companies to sell money and drive up prices.

It can be seen that the problem of gold sales is the focus of this inspection.

Recently, an article written by Ding Yilei, deputy director of the Medical Price and Bidding and Purchasing Department of the National Medical Security Administration, was published on Banner.

Judging from the current policy promotion and the work deployment of relevant departments, the issue of pharmaceutical companies' sales with money and commercial bribery has become the focus of multi-sectoral and multi-dimensional joint crackdowns.

At present, in terms of drug recruitment, commercial bribery of pharmaceutical companies is also severely cracked down.

Procurement with volume to further squeeze the "gray space"

In the previous CCTV news report, regarding the issue of price reductions in the country’s mass procurement, Ding Yilei, deputy director of the Drug Price and Recruitment Department of the National Medical Insurance Administration, said that in the past, there was still a certain amount of gray space in this link when drugs were used in hospitals at the terminal , Because the volume purchase is to guarantee the supply, the company can guarantee sales without the gray space, which is also the source of the room for price reduction.

At the Medical Reform Summit Forum of the 3rd World Health Expo held recently, in response to the past problems in drug recruitment and procurement, Zhang Ming, head of the expert group of the Medical Price and Bidding and Procurement Guidance Center of the National Medical Insurance Administration, said: First, the decoupling of volume and price is common.

It is understandable that the "gray space" and "false heights" mentioned above have a lot to do with cash sales and drug rebates.

With the advancement of national centralized procurement and local mass procurement, the "gray space" of pharmaceuticals has been continuously squeezed.
At present, four batches of national centralized procurement have been completed, and the fifth batch of national centralized procurement has officially started to report.
A new round of drug price reductions is about to strike.

In the future, more and more varieties will be included in mass procurement.
For pharmaceutical companies, the idea of ​​relying on marketing to prop up the market will not work.
Companies must adjust their marketing models in accordance with policies and markets in order to usher in better development.
And those pharmaceutical companies that are not compliant and have no sense of innovation will gradually be eliminated in the big waves.